Breakfast Symposium 5
Breakfast Symposium 6
Breakfast Symposium 7
Breakfast Symposium 8
Oral Presentation 3
CSATVB-KSoLA Joint Symposium
Symposium 20
Symposium 21
Plenary Lecture 2
Keynote Lecture 2
Luncheon Symposium 5 (K)
Luncheon Symposium 6
Luncheon Symposium 7
Special Lecture 2 (K)
2025 KSoLA Awards for Scientific Excellence & Young Investigator (K)
KosFoST-KSoLA Joint Symposium
Symposium 22
Symposium 23
Symposium 24
EAS-KSoLA Joint Symposium
Symposium 25
MSA-KSoLA Joint Symposium
09. 13(Sat)
09. 13(Sat) 07:50~08:50 Room 1
09. 13(Sat) 07:50~08:50 Room 3
09. 13(Sat) 07:50~08:50 Room 4
09. 13(Sat) 08:50~10:20 Room 1
09. 13(Sat) 08:50~10:20 Room 2
Long-term Exposure to LDL-cholesterol and Early Cardiovascular Risk Prevention
09. 13(Sat) 08:50~10:10 Room 3
Optimized Management of Cardiometabolic Syndrome in the Elderly: Focus on Multimorbidity and Frailty
- Strategies for managing hyperlipidemia in fragile elderly patients 08:50~09:10
- Optimizing glucose control in fragile elderly patients with cardiometabolic syndrome 09:10~09:30
- How to deal with multimorbidity and frailty for the prevention of cardiovascular disease 09:30~09:50
- Panel Discussion 09:50~10:20
09. 13(Sat) 08:50~10:20 Room 4
From Treatment to Prevention: A Paradigm Shift in Obesity
09. 13(Sat) 10:40~11:20 Room 1,2,3
09. 13(Sat) 11:25~12:05 Room 1,2,3
09. 13(Sat) 13:30~14:40 Room 1,2,3
09. 13(Sat) 14:50~16:20 Room 1
09. 13(Sat) 14:50~16:20 Room 2
Role of Medicinal Foods in Atherosclerosis and Cardiometabolic Disease
09. 13(Sat) 14:50~16:20 Room 3
Atherosclerosis Beyond Traditional Risks: Emerging Clinical Challenges in Comorbid Conditions
- Atherosclerosis and lipid management in cancer survivors: balancing cardiovascular and oncologic risks 14:50~15:10
- Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk equivalent 15:10~15:30
- Atherosclerosis in chronic inflammatory diseases: focus on rheumatoid arthritis and systemic autoimmunity 15:30~15:50
- Panel Discussion 15:50~16:20
09. 13(Sat) 14:50~16:20 Room 4
TBD
09. 13(Sat) 16:20~17:50 Room 1
Dyslipidemia Management in Special Populations
09. 13(Sat) 16:20~17:50 Room 2
The Impact of Remnant Cholesterol on Various Disease Pathologies and Clinical Outcomes
- Remnant cholesterol as a key contributor to atherosclerotic cardiovascular disease (ASCVD): mechanisms and clinical implications 16:20~16:35
- The role of remnant cholesterol in chronic kidney disease (CKD) progression and cardiovascular risk 16:35~16:50
- Association between remnant cholesterol and dementia: potential mechanisms and clinical perspectives 16:50~17:05
- Remnant cholesterol in women’s cardiometabolic health 17:05~17:20
- Panel Discussion 17:20~17:50
09. 13(Sat) 16:20~17:50 Room 3
Emerging Therapeutics Targeting Myocardial-vascular Interaction in Atherosclerotic Disease
- IKKε-deficient macrophages impede cardiac repair after myocardial infarction by enhancing the macrophage-myofibroblast transition 16:20~16:40
- Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis 16:40~17:00
- Roles of MCU in human platelets on platelet aggregation 17:00~17:20
- Panel Discussion 17:20~17:50
09. 13(Sat) 16:20~17:50 Room 4
Recent Evidence in Non-invasive Cardiovascular Risk Assessment Techniques
